Skip to main content
Carla Barrientos Risso on Muck Rack

Carla Barrientos Risso

As seen in: Agroempresario
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carla Barrientos

Contact Carla Barrientos, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Windfall Bio collapses despite $37 million in funding Bajada

|
By Josh Silverman, Carla Barrientos Risso, Louis Stenmark
| Agroempresario
Windfall Bio, the California-based startup that developed technology to convert waste methane into organic fertilizer, has reportedly ceased operations and is now auctioning off major laboratory and bioreactor assets after raising more than $37 million from climate-focused investors. According to AgFunderNews, the company stopped operating in April while still promoting a large-scale expansion strategy for methane bioconversion technology.
Open in Who Shared Issue with article?

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies

|
By Kelly Meza, Ankit Parag Shah, Carla Barrientos Risso
| preprints.org
You are already at the latest version Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically with the introduction of targeted agents, particularly Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). This review summarizes contemporary frontline and relapsed/refractory treatment strategies, with an emphasis on molecular risk stratification, combination and triplet regimens, measurable residual disease (MRD)–guided therapy, and time-limited approaches.
Open in Who Shared Issue with article?
See all 2 articles